COMPANY

Relay Therapeutics, Inc.

HQ: Cambridge, MA source · relaytx.com ↗ · New England

Keywords: oncology genetic disease cryo-EM PIK3CA Mutation HER2- Negative Breast Cancer Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Hormone Receptor Positive Tumor PIK3CA-Related Overgrowth Spectrum Lymphatic Malformations Vascular Malformations CLOVES Syndrome Klippel Trenaunay Syndrome Megalencephaly-capillary Malformation Polymicrogyria Syndrome Vascular Anomalies Advanced NRAS-Mutant Melanoma Advanced NRAS-Mutant Solid Tumors NRAS Mutation NRAS G12D NRAS G13R NRAS G13D NRAS G12V NRAS Q61R NRAS Q61K NRAS Q61L NRAS Q61H RLY-2608 RLY-8161 RLY-5836

Location: Cambridge, MA · source · Aug 6, 2026

Profile checked Oct 10, 2026

$275.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

May 21, 2026 Raise Follow-on offering: $275M (total, as published), announced May 21, 2026. Source: company release on GlobeNewswire. source ↗
Mar 9, 2026 Trial start Phase 1: A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors source ↗
Aug 26, 2025 Trial start 3: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer source ↗
Jun 13, 2025 Trial start 2: A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) source ↗
Mar 29, 2023 Trial start Phase 1: First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors source ↗
Dec 8, 2021 Trial start Phase 1: First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inh source ↗

Upcoming milestones

Apr 30, 2027 (ESTIMATED) · Phase 1 · First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in · NCT05216432
Dec 30, 2027 (ESTIMATED) · Phase 1 · A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors · NCT07584226
Apr 30, 2028 (ESTIMATED) · 3 · Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer · NCT06982521
2031-07 (ESTIMATED) · 2 · A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) · NCT06789913

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $275.0M. Last 2 years.

May 21, 2026 Follow-on offering: $275M (total, as published), announced May 21, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06982521	Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	3	Recruiting	Aug 26, 2025	Apr 30, 2028 (estimated)
NCT06789913	A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)	2	Recruiting	Jun 13, 2025	2031-07 (estimated)
NCT07584226	A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors	Phase 1	Recruiting	Mar 9, 2026	Dec 30, 2027 (estimated)
NCT05216432	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	Phase 1	Recruiting	Dec 8, 2021	Apr 30, 2027 (estimated)
NCT05759949	First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors	Phase 1	Completed	Mar 29, 2023	Mar 18, 2025 (actual)